MAPI Research Trust provides reliable, comprehensive and up-to-date information services to research scientists, pharmaceutical companies, and governmental health agencies involved in the fields of Patient-Reported Outcomes (PRO) and Epidemiology worldwide.
Home SERVICES Questionnaire Licensing
RLS-QOL (Johns Hopkins Restless Legs Syndrome)

Developed by:
Richard P. Allen et al. (USA)

Copyright:
Dr Richard Allen holds the copyright to the original Johns Hopkins Restless Legs Syndrome Quality of Life questionnaire (RLS-QOL) and derivative works including a shared copyright on its translations with some of the companies/ Institutions sponsoring the translations.

Reference publication:
Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health. 2005 Mar-Apr;8(2):157-67.


Conditions of use:

1. User Agreement:

User is required to complete and sign a User Agreement in which specific conditions requested by the Author are detailed.

There are two types of user-agreement, one specific to the use of the RLS-QOL in commercial studies, and one specific to the use of the RLS-QOL in clinical practice and not funded academic research.

2. Access Fees:

carre6 Author's royalty fees:

The use of the RLS-QOL in any academic research study is free from any Author’s royalty fees.

The use of the RLS-QOL by “for profit” organizations is subject to author’s royalty fees:
• Less than 100 administrations/reproductions =  105 €* per study, plus 105 €* per translated version (excluding US English original version)
• 101 to 1,000 administrations/reproductions = 1,050 €* per study, plus 210 €* per translated version (excluding US English original version)
• Greater than 1,001 administrations/reproductions = 2,100 €* per study, plus 210 €* per translated version (excluding US English original version)

carre6 Distribution fees are requested according to the study design and context of use of the questionnaire:

1. In not-funded academic research (1) and individual clinical practice: free of charge

2. In funded academic research (2): 300 €* per study + an additional 50 €* per language version requested.

3. In commercial studies (3) involving "for-profit" organizations: 600 €* per study + an additional 250 €* per language version requested.

* excluding VAT

(1) Not funded academic research: if the project is not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds then fees are waived.

(2) Funded academic research: projects receiving funding from commerce, government, EU should anticipate paying the corresponding fees.

(3) Commercial studies (industry, CRO, any for-profit companies).


Review copy:

Original US English version available for review purpose only. Please click here to access.


Contact information:

MAPI Research Trust

27 rue de la Villette
F - 69003 LYON
Tel: +33 4 72 13 65 75
Fax: +33 4 72 13 55 73
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Please have the appropriate User Agreement -- i.e. "Commercial studies" or "Academic research/Clinical practice" -- completed, dated and signed and return one original copy to MAPI Research Trust by post. As soon as we receive it, we will process your request.

More information on the RLS-QOL on PROQOLID

[ BACK ]
 

2012 05 18

To access our catalog, please click here.

 

New questionnaires distributed by MAPI Research Trust

ACCEPT (Chronic Treatment Acceptance Questionnaire)
Registrat MAPI (France) and MAPI Consultancy

ADRQL (Alzheimer Disease Related Quality of Life)
Black Betty S, Kasper Judith D and Rabins Peter V. - Johns Hopkins Medical INstitutions (USA)

Barthel Index
Florence I. Mahoney and Dorothea W. Barthel.

ESS (Epworth Sleepiness Scale)
Murray W. Johns (Australia)

FIRST (Fibromyalgia Rapid Screening Tool)
Serge Perrot & Didier Bouhassira (France)

PDSS-2 (Parkinson's Disease Sleep Scale)
Ray Chaudhuri (UK), Claudia Trenkwalder (Germany), Ralf Kohnen (Germany)

Skindex questionnaire 
Mary-Margaret Chren (USA)

TRIM-D and TRIM-D Device (Treatment Related Impact Measure for Diabetes)
Novo Nordisk (Denmark)